| Literature DB >> 26264040 |
Yan-Ling Zheng1, Feng Lian2, Qian Shi3, Chi Zhang4, Yi-Wei Chen5, Yu-Hao Zhou6, Jia He7.
Abstract
BACKGROUND: The prevalence of alcohol intake is increasing among women in some populations. Alcohol consumption plays an important role in the risk of major cardiovascular outcomes and total mortality. Here, we conducted a meta-analysis to estimate the association between alcohol intake and major cardiovascular outcomes or total mortality in women compared with men.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26264040 PMCID: PMC4533962 DOI: 10.1186/s12889-015-2081-y
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Fig. 1Flow diagram of the literature search and studies selection process
Baseline characteristic of studies included
| Study | Country | Sex | Study design | Sample size | Age at baseline | Ex-drinker (%) | Light alcohol (%) | Moderate alcohol (%) | Heavy alcohol (%) | Follow-up (year) | Main outcomes | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Framingham [ | US | Men | Cohort | 3871 | >50 | 19.9 | 30.0 | 14.7 | 35.4 | 10.0 | Ischemic stroke | 8 |
| Women | Cohort | 5300 | >50 | 37.9 | 39.1 | 9.6 | 13.4 | |||||
| DANCOS [ | Denmark | Men | Cohort | 12994 | 19–75 | 14.4 | 27.8 | 41.5 | 16.3 | 6.9 | Coronary disease, total mortality | 7 |
| Women | Cohort | 13794 | 20–79 | 27.9 | 39.8 | 28.8 | 3.8 | |||||
| EPOZ [ | Netherlands | Men | Cohort | 760 | - | 6.7 | 17.6 | 38.6 | 37.1 | 10.0 | Cardiac death, total mortality | 6 |
| Women | Cohort | 860 | - | 18.4 | 29.3 | 34.9 | 17.4 | |||||
| MPC [ | US | Men | Cohort | 13870 | >30 | 60.9 | 14.4 | 10.0 | 12.8 | 20.0 | Coronary disease, stroke, total mortality | 7 |
| Women | Cohort | 13808 | >30 | 85.6 | 8.4 | 3.2 | 2.2 | |||||
| NHEFS [ | US | Men | Cohort | 768 | 46.3 | 17.8 | 63.8 | 7.0 | 11.5 | 17.0 | Total mortality | 5 |
| Women | Cohort | 1286 | 45.7 | 36.7 | 56.5 | 3.2 | 3.7 | |||||
| Whitehall II [ | UK | Men | Cohort | 6840 | 35–55 | 13.0 | 45.6 | 12.6 | 28.7 | 11.0 | Coronary disease, total mortality | 7 |
| Women | Cohort | 3374 | 35–55 | 29.1 | 54.8 | 11.4 | 4.7 | |||||
| MONICA/KORA-Augsburg [ | Germany | Men | Cohort | 1345 | 35–64 | 7.4 | 19.7 | 23.8 | 34.5 | 10.1 | Total mortality | 7 |
| Women | Cohort | 1365 | 35–64 | 28.3 | 30.0 | 15.8 | - | |||||
| MCCS [ | Australia | Men | Cohort | 15156 | 40–69 | 13.2 | 39.9 | 20.8 | 16.1 | 11.4 | Coronary disease | 8 |
| Women | Cohort | 23044 | 40–69 | 38.3 | 37.3 | 11.0 | - | |||||
| CCHS [ | Denmark | Men | Cohort | 5272 | >20 | 15.3 | - | 51.0 | 33.7 | 20.0 | Coronary disease, total mortality | 9 |
| Women | Cohort | 6642 | >20 | 42.8 | - | 50.4 | 6.8 | |||||
| HPFS and NHS [ | US | Men | Cohort | 43685 | 54 | - | - | - | - | 18-20 | Total stroke, ischemic stroke | 6 |
| Women | Cohort | 71243 | 50 | - | - | - | - | |||||
| LWCS [ | US | Men | Cohort | 4852 | 74 | 21.6 | 24.9 | 27.0 | 26.5 | 12.0 | Cardiac death | 7 |
| Women | Cohort | 8444 | 73 | 27.7 | 35.4 | 21.3 | 15.7 | |||||
| DDCHS [ | Denmark | Men | Cohort | 26035 | 50–65 | 4.9 | 52.3 | 11.9 | 30.9 | 5.7 | Coronary disease | 8 |
| Women | Cohort | 29427 | 50–65 | 15.8 | 66.0 | 9.2 | 9.0 | |||||
| JACC [ | Japan | Men | Cohort | 34776 | 40–79 | 22.5 | 17.6 | 23.2 | 29.9 | 14.2 | Cardiac death, total mortality, stroke, ischemic stroke | 9 |
| Women | Cohort | 48906 | 40–79 | 83.5 | 12.0 | 2.1 | 0.7 | |||||
| EPIC-Nutrition-Heidelberg [ | Germany | Men | Cohort | 11062 | 42–62 | 30.0 | 31.0 | 30.0 | 9.0 | 12.0 | Total stroke | 7 |
| Women | Cohort | 12865 | 37–62 | 60.0 | 22.0 | 13.0 | 5.0 | |||||
| EPIC-Potsdam [ | Germany | Men | Nested case-cohort | 815 | 35–65 | 3.2 | 33.4 | 24.5 | 38.9 | 8.2 | Coronary disease, stroke | 6 |
| Women | Nested case-cohort | 1360 | 35–65 | 2.6 | 81.9 | 14.1 | 7.4 | |||||
| EPIC-Spanish [ | Spain | Men | Cohort | 15630 | 29–69 | 4.0 | 13.5 | 32.6 | 41.3 | 10.0 | Coronary disease | 7 |
| Women | Cohort | 25808 | 29–69 | 35.1 | 33.8 | 21.3 | 3.0 | |||||
| Lifestyle and health study [ | Netherlands | Men | Nested case-cohort | 1961 | 45–70 | - | - | - | - | 5.0 | Coronary disease, total mortality | 5 |
| Women | Nested case-cohort | 1713 | 45–70 | - | - | - | - | |||||
| NHIS [ | US | Men | Cohort | 10998 | >18 | - | 23.0 | 30.0 | 47.0 | 14.0 | Cardiac death, total mortality | 8 |
| Women | Cohort | 9767 | >18 | - | 33.3 | 36.6 | 31.1 |
Summary of the relative risks (ratios) of major cardiovascular outcomes and total mortality
| Outcomes | Categories of alcohol intake | Men (RR and 95 % CI) | Women (RR and 95 % CI) | Women compared with men (RRR and 95 % CI) |
|---|---|---|---|---|
| Coronary disease | Low | 0.67 (0.47–0.97)* | 0.70 (0.51–0.97)* | 1.01 (0.84–1.21) |
| Moderate | 0.68 (0.50–0.93)* | 0.70 (0.52–0.94)* | 0.96 (0.75–1.23) | |
| Heavy | 0.69 (0.49–0.96)* | 0.66 (0.44–0.99)* | 0.90 (0.66–1.22) | |
| Total mortality | Low | 0.74 (0.60–0.92)* | 0.87 (0.71–1.07) | 1.07 (0.98–1.17) |
| Moderate | 0.80 (0.68–0.95)* | 0.95 (0.83–1.08) | 1.10 (1.00–1.21)* | |
| Heavy | 1.00 (0.81–1.22) | 1.20 (0.99–1.46) | 1.09 (0.99–1.21) | |
| Cardiac death | Low | 0.93 (0.85–1.01) | 0.84 (0.71–0.99)* | 0.93 (0.83–1.04) |
| Moderate | 0.85 (0.78–0.92)* | 0.86 (0.68–1.08) | 0.99 (0.87–1.14) | |
| Heavy | 0.93 (0.70–1.23) | 1.04 (0.74–1.46) | 1.14 (0.99–1.32) | |
| Stroke | Low | 0.89 (0.79–1.00) | 0.89 (0.76–1.06) | 0.99 (0.83–1.16) |
| Moderate | 0.91 (0.81–1.02) | 0.79 (0.69–0.91)* | 0.90 (0.74–1.10) | |
| Heavy | 1.19 (0.93–1.52) | 1.37 (0.92–2.04) | 1.35 (0.77–2.35) | |
| Ischemic stroke | Low | 0.83 (0.69–0.99)* | 0.79 (0.68–0.92)* | 0.94 (0.74–1.20) |
| Moderate | 0.91 (0.77–1.08) | 0.81 (0.67–0.96)* | 0.88 (0.66–1.16) | |
| Heavy | 1.18 (0.96–1.44) | 1.12 (0.86–1.45) | 1.04 (0.80–1.36) |
*P < 0.05
Subgroup analysis of coronary disease and total mortality of alcohol intake versus the lowest intake for women compared with men
| Outcomes | Subgroup | Low alcohol intake | Moderate alcohol intake | Heavy alcohol intake |
|---|---|---|---|---|
| Coronary disease | Country | |||
| US | 1.24 (0.72–2.13) | 2.17 (1.12–4.21)* | 1.25 (0.52–3.01) | |
| Other | 0.98 (0.80–1.20) | 0.89 (0.75–1.23) | 0.87 (0.62–1.22) | |
| Sample size | ||||
| >10000 | 0.96 (0.80–1.16) | 0.98 (0.73–1.30) | 0.89 (0.63–1.25) | |
| <10000 | 1.42 (0.82–2.45) | 0.93 (0.49–1.78) | 1.00 (0.40–2.49) | |
| Adjusted physical activity | ||||
| Yes | 1.01 (0.80–1.27) | 0.86 (0.66–1.12) | 0.85 (0.65–1.11) | |
| No | 0.96 (0.63–1.48) | 1.24 (0.75–2.05) | 0.91 (0.35–2.38) | |
| Adjusted serum cholesterol | ||||
| Yes | 1.08 (0.84–1.38) | 0.96 (0.72–1.28) | 1.20 (0.80–1.78) | |
| No | 0.93 (0.68–1.27) | 1.00 (0.64–1.57) | 0.75 (0.52–1.08) | |
| Adjusted hypertension | ||||
| Yes | 1.09 (0.85–1.40) | 0.76 (0.49–1.17) | 1.10 (0.68–1.80) | |
| No | 0.92 (0.68–1.26) | 1.11 (0.83–1.48) | 0.77 (0.51–1.15) | |
| Adjusted diabetes | ||||
| Yes | 0.99 (0.78–1.27) | 0.82 (0.61–1.09) | 0.86 (0.66–1.12) | |
| No | 1.01 (0.72–1.40) | 1.22 (0.84–1.78) | 0.83 (0.35–1.97) | |
| Follow-up duration | ||||
| More than 10 years | 1.01 (0.72–1.40) | 1.09 (0.83–1.43) | 0.86 (0.49–1.54) | |
| Less than 10 years | 0.99 (0.78–1.27) | 0.75 (0.48–1.17) | 0.87 (0.63–1.21) | |
| Study quality (NOS score) | ||||
| 8 or 9 | 0.76 (0.50–1.16) | 0.93 (0.74–1.17) | 0.70 (0.42–1.17) | |
| <8 | 1.12 (0.90–1.39) | 0.98 (0.63–1.54) | 1.09 (0.76–1.55) | |
| Total mortality | Country | |||
| US | 1.06 (0.94–1.20) | 1.14 (0.97–1.33) | 1.16 (1.02–1.33)* | |
| Other | 1.08 (0.94–1.24) | 1.07 (0.96–1.20) | 1.01 (0.87–1.18) | |
| Sample size | ||||
| >10000 | 1.06 (0.96–1.16) | 1.09 (0.99–1.19) | 1.08 (0.98–1.20) | |
| <10000 | 1.36 (0.91–2.01) | 1.25 (0.77–2.03) | 1.63 (0.87–3.06) | |
| Adjusted physical activity | ||||
| Yes | 1.10 (0.96–1.26) | 1.08 (0.96–1.20) | 1.02 (0.87–1.18) | |
| No | 1.05 (0.93–1.18) | 1.13 (0.97–1.32) | 1.16 (1.01–1.33)* | |
| Adjusted serum cholesterol | ||||
| Yes | 1.15 (0.73–1.80) | 1.21 (0.79–1.86) | 1.28 (0.61–2.65) | |
| No | 1.07 (0.97–1.17) | 1.09 (0.99–1.19) | 1.09 (0.98–1.21) | |
| Adjusted hypertension | ||||
| Yes | 1.08 (0.94–1.24) | 1.08 (0.87–1.34) | 1.07 (0.83–1.37) | |
| No | 1.06 (0.94–1.20) | 1.10 (0.99–1.21) | 1.10 (0.98–1.23) | |
| Adjusted diabetes | ||||
| Yes | 1.08 (0.93–1.24) | 1.07 (0.96–1.20) | 1.01 (0.87–1.18) | |
| No | 1.07 (0.95–1.20) | 1.13 (0.97–1.31) | 1.16 (1.02–1.33)* | |
| Follow-up duration | ||||
| More than 10 years | 1.08 (0.98–1.19) | 1.09 (0.99–1.20) | 1.10 (0.99–1.22) | |
| Less than 10 years | 0.99 (0.72–1.37) | 1.24 (0.76–2.03) | 1.04 (0.76–1.43) | |
| Study quality (NOS score) | ||||
| 8 or 9 | 1.08 (0.95–1.23) | 1.08 (0.97–1.21) | 1.03 (0.88–1.20) | |
| <8 | 1.06 (0.93–1.21) | 1.11 (0.95–1.30) | 1.15 (1.00–1.31)* | |